A Novel Muscarinic Antagonist R2HBJJ Inhibits Non-Small Cell Lung Cancer Cell Growth and Arrests the Cell Cycle in G0/G1

Nan Hua*, Xiaoli Wei*, Xiaoyan Liu, Xiaoyun Ma, Xinhua He, Rengong Zhuo, Zhe Zhao, Liyun Wang, Haitao Yan, Bohua Zhong, Jianquan Zheng*

Beijing Institute of Pharmacology and Toxicology, Beijing, China

Abstract

Lung cancers express the cholinergic autocrine loop, which facilitates the progression of cancer cells. The antagonists of mAChRs have been demonstrated to depress the growth of small cell lung cancers (SCLCs). In this study we intended to investigate the growth inhibitory effect of R2HBJJ, a novel muscarinic antagonist, on non-small cell lung cancer (NSCLC) cells and the possible mechanisms. The competitive binding assay revealed that R2HBJJ had a high affinity to M3 and M1 AChRs. R2HBJJ presented a strong anticholinergic activity on carbachol-induced contraction of guinea-pig trachea. R2HBJJ markedly suppressed the growth of NSCLC cells, such as H1299, H460 and H157. In H1299 cells, both R2HBJJ and its leading compound R2-PHC displayed significant anti-proliferative activity as M3 receptor antagonist darifenacin. Exogenous replenish of ACh could attenuate R2HBJJ-induced growth inhibition. Silencing M3 receptor or ChAT by specific-siRNAs resulted in a growth inhibition of 55.5% and 37.9% on H1299 cells 96 h post transfection, respectively. Further studies revealed that treatment with R2HBJJ arrested the cell cycle in G0/G1 by down-regulation of cyclin D1-CDK4/6-Rb. Therefore, the current study reveals that NSCLC cells express an autocrine and paracrine cholinergic system which stimulates the growth of NSCLC cells. R2HBJJ, as a novel mAChRs antagonist, can block the local cholinergic loop by antagonizing predominantly M3 receptors and inhibit NSCLC cell growth, which suggest that M3 receptor antagonist might be a potential chemotherapeutic regimen for NSCLC.

Citation: Hua N, Wei X, Liu X, Ma X, He X, et al. (2012) A Novel Muscarinic Antagonist R2HBJJ Inhibits Non-Small Cell Lung Cancer Cell Growth and Arrests the Cell Cycle in G0/G1. PLoS ONE 7(12): e53170. doi:10.1371/journal.pone.0053170

Introduction

Lung cancer is the leading cause of cancer-related mortality worldwide and the number of cases and deaths related to lung cancer is on the rise in many parts of the world. Non-small cell lung carcinoma (NSCLC) accounts for nearly 80% of all cases of lung cancer. Despite aggressive efforts, treatments are unsatisfactory and survival rates remain dismal (<20%) [1]. Therefore, further understanding of the biology of NSCLC and development of novel therapeutic approaches for lung cancer treatment are needed.

Acetylcholine (ACh) is an important neurotransmitter in the central and peripheral nervous systems and plays key roles in learning, memory, autonomic control, and muscular contraction via activation of acetylcholine receptors (AChRs), including the muscarinic (mAChRs) and nicotinic receptors (nAChRs). Recently, it has been found that ACh is also widely synthesized by a variety of non-neuronal cell types, including airway epithelial cells [2], pulmonary pleura [3], small and large intestine, gall bladder, keratinocytes [4], glia [5], vascular endothelium [6] and most common cancer cells such as NSCLC, small cell lung carcinoma (SCLC), colon cancer, glial and ovarian carcinomas [7]. The widespread expression of non-neuronal acetylcholine is accompanied by the ubiquitous presence of choline acetyltransferase (ChAT), cholinesterase and receptors (nAChRs, mAChRs). Although the primary function elucidated incompletely, non-neuronal acetylcholine appears to be involved in the regulation of important cell functions, such as mitosis, trophic function, automaticity, locomotion, ciliary activity, cell-cell contact, cytoskeleton, as well as barrier and immune functions [7–9]. Therefore, the non-neuronal cholinergic system and acetylcholine, acting as a local autocrine and paracrine hormone, should be discriminated from the neuronal cholinergic system and neuronal acetylcholine.

Similarly, non-neuronal ACh stimulates cell growth through either muscarinic cholinergic or nicotinic cholinergic pathways. It has been reported that the growth of tumor cells was accelerated via activation of mAChRs in colon [10], lung [11–12], glial [13], and prostate [14]. In ovarian carcinosmas, expression of mAChR correlates with a poor prognosis [15]. Song et al reported that interruption of autocrine muscarinic cholinergic signaling with M3 receptor antagonist 1,1-dimethyl-4-diphenylacetoxypiperidinium iodide (4-DAMP) or darifenacin has potential to inhibit SCLC cell growth both in vitro and in vivo [16]. In addition, many investigators have shown that activation of nAChRs by nicotine or its carcinogen derivative 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNK)
stimulated tumor cells growth in breast [17], lung [18], pleural mesothelioma [19], colon [20], bladder [21] and cervical cancer [22]. These studies have shown that α7 is the main nAChR subunit that mediates the proliferative effects of nicotine in cancer cells. 

Pencyclidine hydrochloride (PHC) is an anti-cholinergic drug derived from hyoscymamine and developed independently by our institute. As its potential anticholinergic activity, it has been marketed for treatment of acute organophosphorus pesticides poisoning and chronic obstructive pulmonary disease (COPD) [23–24]. PHC is a racemic compound with two chiral centers, which compose four optical isomers (Fig. 1). Our previous work revealed that the isomer with R, R-configuration (R2-PHC) displays the highest anticholinergic activity. To reduce the side effects by depressing access to the central nervous system, a new anticholinergic agent (R2HBJJ) is designed by introducing a quaternary ammonium salt group to R2-PHC molecule for treatment of peripheral diseases, such as lung cancers and COPD. In the present study, the selectivity of R2HBJJ for M1–M5 receptors is evaluated in detail and the antitumor activity of R2HBJJ on NSCLC cell lines in vitro and its potential mechanisms are explored. To our knowledge, this is the first study to investigate the effect of M3 antagonist on NSCLC cells.

Results

R2HBJJ displayed higher selective affinity to M3 and M1 receptor subtypes

Saturation binding analysis yielded affinity binding constant \( K_D \) values for \([3\text{H}] \text{NMS} \) at human M1, M2, M3, M4 and M5 of 0.29±0.04, 0.81±0.17, 0.53±0.09, 0.19±0.03, and 0.48±0.13 nM, respectively. The relative selectivity for M1–M5 AChR subtypes of R2HBJJ was first determined at the level of receptor binding affinity in human mACHRs proteins (Fig. 2). The values of IC\(_{50}\) and \( K_I \) of R2HBJJ inhibiting \([3\text{H}] \text{NMS} \) binding to M1–M5 receptor subtypes were summarized in Table 1. R2HBJJ exhibited a relative higher affinity to M3 and M1 receptor than M2 receptor. The rank of affinity of R2HBJJ for five different mACHRs was M3>M1>M4>M5>M2.

R2HBJJ inhibited carbachol-induced tracheal contraction

To determine the blocking effect of R2HBJJ on mACHr, an ex vivo model of guinea-pig tracheal contraction was applied. The contraction of tracheal strip isolated from guinea-pig was induced by 1 \( \mu \)M of carbachol, a non-selective muscarinic agonist. And then, increasing concentrations of R2HBJJ (10\(^{-10}\)–10\(^{-6.5}\) M) or atropine as a control antagonist, were added cumulatively into the organ bath. The inhibitory contraction response against carbachol-induced contraction was obtained. The results showed that R2HBJJ concentration-dependently inhibited the contractile responses of guinea-pig trachea to the carbachol (Fig. 3). The 50% inhibition concentration (IC\(_{50}\)) was 7.58±1.05 nM, which was statistically significantly less than that of atropine (10.21±1.04 nM, \( P<0.05 \)). The data revealed that R2HBJJ exhibited a strong antagonistic activity on mACHRs expressed in guinea-pig trachea.

NSCLC cell lines expressed cholinergic receptors and choline acetyltransferase

If a cholinergic autocrine loop is functional in NSCLC, then cells must express choline acetyltransferase (ChAT), mACHRs and/or nAChRs for ACh to provide autocrine cholinergic stimulation to NSCLC cell growth. To determine whether NSCLC cell lines express AChRs and ChAT, the mRNAs of five subtypes of mACHRs (M1–M5), three subtypes of nAChRs (α7, δ9 and α10) and ChAT were examined by RT-PCR in human NSCLC cell lines H1299, H157, H460, A549 and human immortalized bronchi epithelial cell BEP2D. As shown in Fig. 4, the M1, M2, M5, α7, δ9, α10 receptor subtypes and ChAT were almost expressed in all of the NSCLC cells tested. M3 receptor subtype was expressed in H1299, H157 and H460, and was absent in A549. M4 receptor subtype was expressed in H1299 and H157, but not in H460 and A549. In contrast, human immortalized bronchi epithelial cell BEP2D expressed the mRNAs of different AChRs subtypes in lower levels, except for α10 subtype and ChAT. The results imply an acetylcholine autocrine loop existing in NSCLC cells.

R2HBJJ Inhibits NSCLC cell proliferation in vitro

To evaluate the effect of R2HBJJ on cell growth of NSCLCs, the cells were treated with increasing concentrations of R2HBJJ (1.6–100 \( \mu \)M) for 72 h and cell viability was determined by using the sulforhodamine B (SRB) assay. The results showed that treatment with R2HBJJ markedly suppressed cell growth in a concentration-dependent manner in H1299, H460 and H157 cells, with a 50% growth-inhibitory concentration (GI\(_{50}\)) of 3.5, 8.8 and 28.5 \( \mu \)M, respectively. In comparison, A549 and BEP2D cells were resistant to R2HBJJ, with a GI\(_{50}\) of more than 100 \( \mu \)M, the highest concentration tested (Fig. 5A). The data suggested that the anti-proliferative effect of R2HBJJ was dependent on the characteristics of cell lines and not the non-selective cytotoxicity.

Furthermore, the effects of other mACHRs (Fig. 5B) and nAChRs (Fig. 5C) antagonists on H1299 were observed. As shown in Fig. 5B and 5C, the known selective M3 mACHR antagonists darifenacin significantly inhibited H1299 cell proliferation in a concentration-dependent manner, whereas the non-selective mACHR antagonist atropine, non-selective nACHR antagonist mecamylamine, selective M1 mACHR antagonist pirenzepine, selective α4/α7/α4 antagonist DihE, and selective α7 antagonist α-bgt had no obvious effects on cell proliferation. The M2/M4-selective antagonist AF-DX116 also had inhibition on cell proliferation at the highest concentration tested. In comparison, R2HBJJ and its parental compound R2-PHC significantly inhibited H1299 cell proliferation in a concentration-dependent manner, which inhibitory potency was about 3.7-fold greater than that of darifenacin, the best one among the antagonists tested above. Because no exogenous ACh agonist was applied, the data revealed that endogenous ACh functioned as an autocrine growth factor signaling in human NSCLC cells, in part through activation of M3 receptor.

Exogenous ACh agonist attenuated R2HBJJ-induced growth inhibition

To determine the correlation between cholinergic signal pathways and R2HBJJ-induced growth inhibition, exogenous AChR agonist ACh was used. The effects of ACh on the growth of H1299 and on R2HBJJ-induced growth inhibition were observed.

![Figure 1. Structures of R2HBJJ and its parental compounds.](doi:10.1371/journal.pone.0053170.g001)
It was found that exogenous ACh alone at 1, 10, and 100 μM for 72 h had no significant effects on H1299 cell growth (Table 2). R2HBJJ alone at 10 μM and 20 μM decreased the cell viability from 100 ± 1.61% to 54.13 ± 3.89% and 23.23 ± 2.14% (n = 3), respectively. When ACh was administered prior to R2HBJJ treatment, the growth inhibition induced by R2HBJJ (both 10 and 20 μM) was attenuated in the presence of exogenous ACh in a concentration dependent manner. Two-way analysis of variance (ANOVA) showed a significant effect of R2HBJJ treatment, ACh treatment, and R2HBJJ treatment ×ACh treatment interaction (P<0.0001, respectively). Post-hoc tests confirmed that the following pretreatment concentrations of ACh, 10 μM and 100 μM, significantly attenuated the growth inhibition induced by 10 μM or 20 μM of R2HBJJ. When compared with R2HBJJ treatment alone at the level of 10 μM, 10 μM and 100 μM of ACh pretreatment increased the cell viability from 54.13 ± 3.89% to 82.29 ± 5.62% (P<0.01) and 91.1 ± 3.65% (P<0.01), respectively. When compared with R2HBJJ treatment alone at the level of 20 μM, 10 μM and 100 μM of ACh pretreatment increased the cell viability from 23.23 ± 2.14% to 35.57 ± 4.48% (P<0.05) and 58.55 ± 2.83% (P<0.01), respectively (Table 2).

Table 1. Selective effects of R2HBJJ on muscarinic acetylcholine receptor subtypes (mol/L, mean ± SD, n = 3).

| Subtype | IC50 | Ki |
|---------|-----|----|
| M1      | (7.39 ± 1.45) x 10^{-10} | (7.86 ± 3.39) x 10^{-11} |
| M2      | (5.33 ± 2.89) x 10^{-9}  | (1.33 ± 0.52) x 10^{-9}  |
| M3      | (3.80 ± 2.63) x 10^{-10} | (6.79 ± 3.71) x 10^{-11} |
| M4      | (1.47 ± 1.89) x 10^{-9}  | (1.06 ± 0.12) x 10^{-10} |
| M5      | (1.61 ± 2.37) x 10^{-9}  | (2.64 ± 0.98) x 10^{-10} |

doi:10.1371/journal.pone.0053170.t001
M3- and ChAT specific siRNAs decreased cancer cell proliferation

To further demonstrate that endogenous ACh and M3 receptor signal were involved in cell proliferation of human NSCLC cells, H1299 cells were transfected with M3- or ChAT-specific siRNAs and their proliferation was observed over time. Firstly, western blot analysis was used to identify the levels of these genes. As shown in Fig. 6A and 6B, M3 and ChAT protein levels were strongly decreased 72 h after transfection with targeting siRNAs compared to the negative control siRNA. By using SRB assay at 96-well plate, the potency of growth inhibition caused by silencing M3 or ChAT was tested at 48, 72 and 96 h post transfection. The result revealed that there was a time-dependent reduction of cell growth viability by M3- or ChAT-siRNA in H1299 cells compared to the negative control siRNA (Fig. 6C). The anti-proliferative effect of silencing M3 was visualized evidently early at 48 h post transfection (P<0.01) and the inhibition of 55.5% was achieved within a 96 h time frame (P<0.001). For ChAT-siRNA, its anti-proliferative effect was presented at 72 h post transfection (P<0.001), which was slower than M3 siRNA; and the inhibition of 37.9% was achieved 96 h post transfection compared to the negative control siRNA (Fig. 6C, P<0.001).

To further evaluate whether the anti-proliferative effect of R2HBJJ was M3 receptor specific, H1299 cells were treated with R2HBJJ after M3 siRNA transfection. The result showed that in negative siRNA treated cells, R2HBJJ exhibited significant cell growth inhibition, the cell viability were 83.5% (P<0.05) and 57.4% (P<0.01) after R2HBJJ 8 μM and 16 μM treatment. However, after the cells were treated with M3 siRNA, the cell viability was inhibited to 54.4%; R2HBJJ (8 μM and 16 μM) didn’t further influence the cell growth, which suggested that silencing M3 receptor deprived cellular sensitivity to R2HBJJ and accentuated the role of M3 in the effect of R2HBJJ (Fig. 6D).

R2HBJJ arrested the cell cycle in G0/G1 phase

To explore the potential mechanisms of R2HBJJ-induced cell death in NSCLC cells, the effects of R2HBJJ on cell cycle progression were observed by using the flow cytometric analysis. The results from H1299 cells showed that the percentage of G0/
the decrease of phosphorylated Rb after R2HBJJ treatment. Further we evaluated the concentration response of Rb phosphorylation reduced after treatment with R2HBJJ for 48 h (Fig. 8B). The result showed that the decrease of Rb phosphorylated at Ser807/811 by R2HBJJ was concentration-dependent and occurred at the lowest concentration tested (1.25 mM). Consistently, the down-regulation of Cyclin D1, CDK4 and CDK6 proteins was observed in the cells treated by increasing concentrations of R2HBJJ. Similarly, the expression of basal Rb showed a significant increase over concentration at first and then rapidly declined to basal level. Together, these results suggested that Rb protein and the kinase composite of cyclin D1/CDK4, 6 were predominantly involved in the cellular G0/G1 arrest induced by R2HBJJ.

Discussion

Many studies have demonstrated that ACh and other components of cholinergic signaling, including ChAT, cholinesterase, M and N cholinergic receptors, are present in a variety of non-neuronal tissues, including most common cancer cells such as NSCLC, SCLC, colon, glial, breast and ovarian carcinomas. In the local environment of tumors, concentrations of ACh at surface receptors may be even higher due to high cell densities in solid masses, increased secretion of ACh proximity to receptor location and decreased levels of cholinesterase in NSCLC [26], which implicates that cholinergic signaling may be further increased. The non-neuronal cholinergic system and ACh, as a local cellular growth signaling, plays a role in the development and progression of cancer and represents a potential new pathway to target tumor growth. Therefore, cholinergic antagonists interrupt the up-regulated autocrine signaling may provide a directed upstream approach to blocking proliferative pathway.

R2HBJJ, as a derivative of anticholinergic agent R2-PHC, was synthesized by our institute. In the present study, we evaluated the selectivity of R2HBJJ for M1–M5 muscarinic receptors and its anticholinergic activity. We also determined if interruption of endogenous cholinergic signaling with R2HBJJ has potential to inhibit NSCLC growth in vitro.

| R2HBJJ (µM) | ACh (µM) | 0 | 1 | 10 | 100 |
|-------------|----------|---|---|----|-----|
| 0           | 100±1.61 | 101.7±1.80 | 104.7±2.74 | 99.05±2.72 |
| 10          | 54.13±3.89 | 55.04±6.79 | 82.29±5.82 | 91.1±3.65 ** |
| 20          | 23.23±2.14 | 24.1±1.94 | 35.57±4.48 | 58.55±2.83 ** |

Two-way ANOVA was used to compare the interaction of two treatment factors. Post-hoc analyses were performed with Bonferroni’s tests.

**P<0.01, compared with the cells treated with 10 µM R2HBJJ alone.

#P<0.05.

**P<0.01, compared with the cells treated with 20 µM R2HBJJ alone.

doi:10.1371/journal.pone.0053170.t002
Our results demonstrated that R2HB[1] had significantly higher affinity for M3 and M1 receptor subtypes than M2 subtype, which suggested fewer M2 receptor-associated cardiovascular side effects. The rank of affinity of R2HB[1] for five different mAChRs was M3>M1>M4>M5>M2. The result is consistent with that obtained in its parental compound PHC before [27]. In the functional study, R2HB[1] inhibited the contractile responses of guinea-pig tracheae to the carbachol in a concentration-dependent manner. The inhibitory activity was stronger than that of mACHR antagonist, atropine.

Song et al reported that SCLC synthesize and secrete acetylcholine, which acts as an autocrine growth factor through both nicotinic and muscarinic cholinergic mechanisms [16]. Our study elucidated human NSCLC cell lines, like SCLC, express both M and N AChRs, as well as ChAT, implying that a functional foundation of cholinergic autocrine loop is present in NSCLC. Therefore, the growth inhibitory activity of R2HB[1] on several NSCLC cell lines, including H1299, H460 and H157 cells, may be mediated by both M and N cholinergic mechanisms. But when H1299 cells were treated with known selective or non-selective antagonists on M- and N- receptors in vitro, we found that only M3 receptor antagonist darifenacin presented a significant inhibition on cell growth. Meanwhile, our compounds R2HB[1] and R2-PHC also markedly inhibited the cell viability of H1299 cells, with a preferable effect than darifenacin. In the study of Song et al, treatment of SCLC cells with M3 receptor antagonists of 4-DAMP or darifenacin inhibited cell growth both in vitro and in vivo. Our results suggest that M3 receptor antagonists have inhibitory activity on NSCLC as well. The anti-proliferative effect of R2HB[1] on NSCLC may be related to its selective M3 receptor antagonistic activity. Russo P et al reported that inhibition of α7-nAChR with a powerful high affinity antagonist α7-βgT induced antitumor activity in NSCLC and pleural mesothelioma by triggering apoptosis [18–19]. However, in our investigation, another α7-nAChR antagonist α7-bgt was used to treat H1299 cell and the effect on cell viability was not observed, which suggested that α7-nAChR signaling may not be the primary mediator in H1299 cell growth.

In the present study, we failed to observe the proliferative effect of exogenous ACh on H1299 cells, which may imply that endogenous ACh has provided enough stimulant effect on cell proliferation. However, exogenous replenish of ACh is needed to antagonize competitively the inhibition of R2HB[1] on H1299 cells. The result stressed that the effect of R2HB[1] on H1299 cell growth was achieved via impacting on endogenous ACh signaling. In the present study, ChAT siRNA was proved to inhibit cell growth, which further supported this hypothesis. Moreover, it is noteworthy that treatment with M3 receptor siRNA resulted in a significant growth inhibition on H1299 cells when compared with negative control siRNA treated cells. The potency of inhibition achieved 50% or more within a 96 h time frame. When M3 receptor was effectively knocked down in H1299 cells, the cells lost their sensitivity to R2HB[1]. The results further accentuated the role of M3 in the anti-proliferative effect of R2HB[1].

Cell cycle arrest is a major mechanism preventing tumor growth. Our results from flow cytometric analysis showed that R2HB[1] markedly suppressed the cell mitotic progression through arresting cells in G0/G1 phase. Cell cycle transition from G1 to S controls DNA synthesis and requires hyperphosphorylation of a tumor suppressor, Rb [28]. In the cycle process, catalytic activity of cyclin D1 associated with CDK4/6 is first manifested by mid-G1, increases to a maximum at the G1/S transition and contributes to G1 exit. Whereas cyclin E and cyclin A associating with CDK2 is activated at the G1/S transition or in the early S phase, respectively. Phosphorylation of Rb is initially triggered by active Cyclin D1-CDK4/6 complexes and later accelerated by Cyclin E-CDK2. This phosphorylation allows the dissociation of transcription factors, such as E2 promoter-binding factor (E2F) and the proto-oncogene c-Abl overexpressed or mutated in a number of malignant tumors, which can transactivate S-phase genes encoding for proteins that amplify the G1-to-S phase switch and are required for DNA replication [29]. Of the cell cycle proteins examined in the present study, the expressions of cyclin D1, CDK4 and CDK6 proteins were down-regulated time-dependently, whereas the levels of cyclin E and CDK2 were not affected significantly. Moreover, the phosphorylation of Rb at the position of Ser^277/281 was inhibited by R2HB[1] time-dependently,
Figure 7. R2HBJJ induced G0/G1 Phase arrest on NSCLC cells. The cells were synchronized with 1% FBS for 24 h. After that, the cells were released into complete medium (10% FBS) containing 20 μM R2HBJJ for 24, 48, 72 h (A, H1299 cells) or various concentrations of R2HBJJ (2.5–20 μM) for 48 h (B, H1299 cells; C, H157 cells). Cells treated with solvent (DMSO) were used as a control. Cell cycle distribution was determined by using flow cytometric assay. The histograms displayed here were representative of three experiments.

doi:10.1371/journal.pone.0053170.g007
which could abolish the interaction between c-Abl and Rb and retard the activation of c-Abl and the cell cycle progression [30]. Together, our data suggested that Rb protein and the kinase composite of cyclin D1/CDK4, 6 were predominantly involved in the cellular G0/G1 arrest induced by R2HBJJ. The results also suggested that R2HBJJ exerted its retarding effect at the early phase of G0/G1.

In fact, regulatory molecules governing early cell cycle progression such as cyclin D1-CDK4/6-Rb are the frequent targets of genetic alterations in an exceptionally high percentage of lung cancers [31]. Many studies have demonstrated that strategies to target proteins associated with early cell cycle progression and the G1 restriction point may be useful in anticancer therapy [32–33]. Cyclin D1 has also been shown to be a downstream target of the G1 restriction point may be useful in anticancer therapy [32–33]. Cyclin D1 has also been shown to be a downstream target of the G1 restriction point may be useful in anticancer therapy [32–33]. Cyclin D1 has also been shown to be a downstream target of the G1 restriction point may be useful in anticancer therapy [32–33].

In conclusion, the current study reveals that NSCLC cells express an autocrine and paracrine cholinergic system which stimulates the growth of NSCLC cells. R2HBJJ, a novel muscarinic antagonist, can block the local cholinergic loop by antagonizing predominantly M3 receptors and inhibit NSCLC cell growth. The mechanism for R2HBJJ-induced cell cycle G0/G1 arrest involves down-regulation of cyclin D1-CDK4/6-Rb. The results suggest that M3 receptor antagonists possibly become a new potent chemotherapeutic regimen for NSCLC.

**Materials and Methods**

**Materials**

Radiolabeled compound [3H] N-methylscopolamine ([3H] NMS), human muscarinic receptor (M1, M2, M3, M4 and M5) proteins and BetaPlate Scint of membrane were obtained from Perkin Elmer Life and Analytical Sciences. R2-PHC and R2HBJJ (chemical structures shown in Fig. 1) were synthesized by our institute. The chemical structures were confirmed by nuclear magnetic resonance spectrum analysis. Atropine, pirenzepine, mecamylamine, α-bungarotoxin (α-bgt), carbachol, and ACh were purchased from Sigma. Dihydro-β-erythroidine hydrobromide (DihβE) and AF-DX116 were purchased from Tocris. Darifenacin was purchased from Beijing Huaefeng United Technology. Antibodies used for western blotting were purchased from CellRapid for retronblastoma tumor suppressor protein (Rb), phospho-Rb (Ser780 and Ser807/811), Cyclin D1, Cyclin E, CDK4, and CDK6. M3-AChR was obtained from Santa Cruz. ChAT, β-actin, goat anti-rabbit and goat anti-mouse immunoglobulin labeled with horseradish peroxidase were purchased from Beijing Zhongshan Jinqiao Biotechnology.

**Radioligand Binding Assay**

Saturation binding was performed using a range of concentrations of [3H] NMS (0.3–19.5 nM; 82 Ci/mmol) in the absence and presence of atropine (500 μM) to determine nonspecific binding. [3H] NMS, mAChRs proteins and R2HBJJ were individually diluted with the binding buffer, which consisted of 110 mM NaCl, 5.3 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 25 mM glucose, 58 mM sucrose, 20 mM HEPES (pH 7.4). Binding assays were performed in a final volume of 0.5 ml containing 18 to 42 μg of receptor protein and were incubated for 2 h at 37°C. Competition binding assays were performed using 2.4 nM of [3H] NMS in the absence and presence of a range of antagonist concentrations (10–6 - 10–13 M). Bound radioligand was separated from free by rapid vacuum filtration through GF/C glass fiber filters (Whatman). The filters were rinsed three times with ice cold PBS. After being dried, the filters were placed in scintillation vials with 0.5 ml of BetaPlate Scint. Radioactivity trapped on the filters was quantified by a BECKMAN Beta counter. The assay was repeated three times with duplicate samples.

**Guinea-pig tracheal contraction**

Female guinea-pigs (350–450 g) were used in this study, which were purchased from Beijing Animal Center. Animal experiments were carried out in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals (1996) and the institutional guidelines of Beijing Institute of Pharmacology and Toxicology. The experimental protocol was approved by the Animal Research Advisory Committee of Beijing Institute of Pharmacology and Toxicology. The experiment was performed as described previously [25]. The animals were killed by a blow to the head. The trachea was excised, cleaned of adhering fat and connective tissue, cut into 2–3 rings, each containing about two cartilages. Each ring was then opened by a longitudinal cut, forming a tracheal chain with the smooth muscle in the center and the cartilaginous portion.
on the edges. The segments were mounted in an organ bath containing 20 ml Krebs-Henseleit (KH) solution of the following composition (mM): NaCl 118.0, KCl 4.7, CaCl2 2.52, MgSO4 1.2, NaHCO3 25.0, KH2PO4 1.2, and glucose 11.0. The tissue bath solution was maintained at 37°C and gassed with 95% O2 plus 5% CO2. Tracheal preparations were equilibrated in the medium for 60 min with four changes of KH solution and maintained under an optimal tension of 1.5 g before specific experiment protocols were initiated. Segments were first pre-contracted with 1 μM carbachol for 10 min till reaching stable plateaus, then washed completely until the segments reached basal tension and maintained in KH solution for another 60 min with four changes. Thereafter, segments were incubated with 1 μM carbachol for 10 min again and the experiments were started with this preparation. R2HBJJ or atropine was then administered cumulatively to produce their concentration-response curves. Results are expressed as percentages of the maximal response for carbachol before the addition of R2HBJJ or atropine. Contractions were recorded isometrically via a force-displacement transducer (SGG-4, Chengdu Scientific Instrument, China) connected to a Four-channel Oscillograph (Yimei Biotechnology, Nanjing, China).

Cell Lines and Cell Culture

Human NSCLC cells H1299, H157, H460 and A549 were commercially obtained from the Cell Resource Center, IBMS, CAMS/PUMC (Beijing, China). The human papillomavirus (HPV18) immortalized bronchi epithelial cell BEP2D was developed by the research group of Dr. Curtis C. Harris (Division of Cancer Etiology, National Cancer Institute, NIH) [35]. Under the generous permission of Dr. Harris, we received the cell line as a gift from Dr. Tom K. Hei (Center for Radiological Research, Columbia University) [36]. H1299, H157 and H460 were routinely cultured in RPMI-1640 medium (Sigma) supplemented with 10% fetal bovine serum (FBS). A549 was maintained in Dulbecco’s modified Eagle’s medium (Hyclone) supplemented with 10% FBS. BEP2D was maintained in serum-free LHC-8 medium (Invitrogen) supplemented with epidermal growth factor and other growth supplements as described previously [35–36]. Cells were cultured at 37°C in a humidified incubator containing 5% CO2.

RT-PCR

Total RNA was extracted from cells using TRIzol reagent (Invitrogen). 1 μg aliquot of each RNA sample was reverse-transcribed to synthesize cDNA in a 20 μl reaction volume by using an AMV-RT kit (Promega). Incubate the reaction using Oligo (dT)15 Primer at 42°C for 60 min, 95°C for 5 min, 4°C for 5 min. PCR was carried out in 25 μl of a reaction mixture with the following conditions: 95°C for 5 min, 35 cycles at 94°C for 30 s, 55°C for 1 min, and 72°C for 1 min. The primers used for PCR were shown in Table 3. GAPDH was used as the loading control. The PCR products were resolved on a 1.5% agarose gel stained with ethidium bromide.

Cell Viability Assay

Cells were seeded at a density of 6.0×10³ cells/well in 96-well plates. After overnight incubation, the cells were treated with R2HBJJ (1.6–100 μM) or other antagonists (0.3–100 μM) for 72 h. The inhibitory effects of the antagonists on cell growth were determined using SRB assay, as described previously [37]. For the combination administration, the agonist was added 1 h before R2HBJJ. Each experiment was performed in six replicates and repeated for three times. Cells treated with solvent (DMSO) were used as a control, with viability set at 100%. The 50% growth-inhibitory concentration (GI50) was calculated with Hill equation after curve fitting by GraphPad Prism 5 software.

Small interfering RNA transfection and assay

The M3 receptor and ChAT specific small interfering RNA (siRNA), the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) positive control siRNA (used in preliminary experiments to optimize the siRNA transfection efficiency, data not shown), the negative control siRNA were designed and synthesized by Guangzhou RiboBio Technology (Guangzhou, China). The target sequences for M3 receptor and ChAT are 5'-CCTGGTATTGGTGCATT-3' and 5'-GCAAGCCATTTGGCAACAAA-3', respectively. The negative control siRNA consists of a proprietary siRNA sequence not corresponding to any eukaryotic gene.

H1299 cells were seeded at 1×10⁵/well in six-well plates one day prior to transfection and 1.5 μL of the medium without antibiotics was added to each well. The siRNA were transfected at a concentration 200 nM each in serum-free Opti-MEM I medium with Lipofectamine™ 2000 reagent (Invitrogen) according to the manufacturer’s instruction. Following 6 h incubation, the transfection medium was replaced with RPMI-1640 containing 10% (v/v) FBS. 72 h after transfection, the cells were harvested for Western blotting analysis. For cell proliferation assay, H1299 cells were seeded at 3.5×10⁵/well in 96-well plates one day prior to transfection. 48 h, 72 h and 96 h after transfection, cell growth viability was respectively determined using SRB assay. An independent experiment was performed to observe the combination effect of M3 siRNA knockdown and R2HBJJ treatment. While the transfection medium was replaced with complete RPMI-1640 medium 6 h after transfection, cells were treated with or without R2HBJJ (8 μM and 16 μM) for 72 h. Each experiment was performed in four replicates and repeated for three times. Cell viability of negative control siRNA was set at 100%.

Cell Cycle Analysis

Alterations in cell cycle were determined by using flow cytometric assay. Cells were seeded at a density of 1×10⁵ cells/well in six-well plates and synchronized by plating in RPMI-1640 containing 1% FBS for 24 h. Time-dependent response, cells were incubated in 2 ml fresh RPMI-1640 containing 10% FBS with 20 μM R2HBJJ for 24, 48, 72 h. For concentration-dependent response, cells were incubated for 48 h with R2HBJJ at final concentrations of 2.5, 5, 10, 15, 20 μM in 2 ml fresh RPMI-1640 containing 10% FBS. Fresh media added in the control well simultaneously. After treatment, the cells were harvested with trypsin, washed once with PBS, and then fixed in 70% ethanol overnight at 4°C. Before flow cytometry analysis, cells were stained with 200 μg/ml Ribonuclease A and 50 μg/ml propidium iodide (Sigma) for 30 min at room temperature away from light. 1×10⁵ cells per sample were analyzed using a FACSCalibur flow cytometer (BD Biosciences). Data were evaluated using Modfit software.

Western Blot

Cells were harvested and subjected to lysis in the buffer X (50 mM Tris, 270 mM NaCl, 1% Triton X-100, pH 7.4). Equal amounts of lysates (30 μg) were separated on 10% SDS-PAGE and then transferred to polyvinylidene difluoride membranes (Millipore). Membranes were then blocked with PBS buffer containing 5% low fat milk and 0.1% Tween 20 (PBST) for 1 h at room temperature and then incubated with primary antibodies (1:1000–2000) overnight at 4°C. After being washed three times...
ANOVA was used to compare the interaction of two treatment calculated by using the Cheng-Prusoff equation. For the experiment fitting program. The inhibition constants (K_i values) were calculated using the Cheng-Prusoff equation. For the experiments of exogenous ACh combined with R2HBJJ, two-way ANOVA was used to compare the interaction of two treatment factors. Post-hoc analyses were performed with Bonferroni's tests for comparisons to controls. For the cell viability assay after siRNA transfection, one-way ANOVA followed by Dunnett’s t test was used. A P value of less than 0.05 was considered statistically significant.

Acknowledgments

We thank National Center of Biomedical Analysis (Beijing, China) for technical contributions to flow cytometric analysis.

Author Contributions

Conceived and designed the experiments: NH XLW JQZ. Performed the experiments: NH XLW HTY JQZ. Analyzed the data: NH XLW HTY JQZ. Contributed reagents/materials/analysis tools: XHH BHZ YXMY. Wrote the paper: NH XLW JQZ.

Table 3. Primers used for RT-PCR.

| Gene   | Primers                                                                 | Length (bp) |
|--------|-------------------------------------------------------------------------|-------------|
| M1     | S: 5′-TGCTTCTCTCCATCTACCTCC-3′ A: 5′-GTTTGGTCAAGCGCCCTTCT-3′            | 429         |
| M2     | S: 5′-ACCATCTTGGAACACATC-3′ A: 5′-CATTATACATCGGTCATTGGTCC-3′            | 321         |
| M3     | S: 5′-ACCGTCACACTTCCATAG-3′ A: 5′-GATGTTTGCTGTGGTCCT-3′                  | 449         |
| M4     | S: 5′-CATGAGAGGCTGTTGACATGTTGTCCT-3′ A: 5′-ACGGGGGCTACTGCTACACT-3′       | 391         |
| a7     | S: 5′-GCTACCGGTCTTCTGCTATG-3′ A: 5′-ATCCGGCTCTTGATGATAG-3′              | 442         |
| a9     | S: 5′-CTGTTCCGTTTTGCTC-3′ A: 5′-GGAAGGCTGCTACATC-3′                     | 403         |
| a10    | S: 5′-CTGTTCCGTTTTGCTC-3′ A: 5′-GGAAGGCTGCTACATC-3′                     | 388         |
| ChAT   | S: 5′-GGAGATGTTCTGCTGCTATG-3′ A: 5′-GGAAGTGAAACCTAGTGAGGA-3′             | 280         |
| GAPDH  | S: 5′-AGGTCGGAGTCAACGGATTTG-3′ A: 5′-GGAGGTGAAACCTAGTGGCA-3′             | 532         |

References

1. Ramalingam SS, Owonikoko TK, Khuri FR (2011) Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 61: 91–112.
2. Proskocil BJ, Sekhon HS, Jia Y, Savchenko V, Blakely RD, et al. (2004) Expression of the M1 acetylcholine receptor in airway bronchial epithelial cells. Endocrinology 145: 2490–2506.
3. Klaproth H, Reinhirmer T, Metzen J, Münch M, Rittinger F, et al. (1997) Non-neuronal acetylcholine, a signaling molecule synthesized by surface cells of rat and man. Naunyn Schmiedebergs Arch Pharmacol 355: 515–523.
4. Grando SA, Kat DA, Qi M, Dahl MV (1993) Human keratinocytes synthesize, secrete, and degrade acetylcholine. J Invest Dermatol 101: 32–36.
5. Wesler I, Reuhenheimer T, Klaproth H, Schneider EJ, Racké K, et al. (1997) Mammalian glial cells in culture synthesize acetylcholine. Naunyn Schmiedebergs Arch Pharmacol 356: 694–697.
6. Haberberger RV, Bodenbenner M, Kummer W (2000) Expression of the cholinergic gene locus in pulmonary arterial endothelial cells. Histochem Cell Biol 113: 379–387.
7. Shah N, Kharuna S, Cheng K, Raufman JP (2005) Muscarinic receptors and ligands in cancer. Am J Cell Physiol 286: G221–G232.
8. Wesler I, Kispalagyi CJ, Racké K (1998) Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: expression and function in humans. Pharmacol Ther 77: 9–79.
9. Egleton RD, Brown KC, Dasgupta P (2007) Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis. Trends in Pharmacol Sciences 29: 151–158.
10. Cheng K, Sanimi R, Xia G, Shani J, Drachenberg C, et al. (2008) Acetylcholine release by human colon cancer cells mediates autocrine stimulation of cell proliferation. Am J Physiol Gastrointest Liver Physiol 295: G501–G507.
11. Song P, Sekhon HS, Fu XW, Maior M, Jia Y, et al. (2008) Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Res 68: 4693–4700.
12. Song P, Sekhon HS, Jia Y, Keller JA, Bhatnajaj JK, et al. (2003) Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res 63: 214–221.
13. Yagle K, Lu H, Guizzetti M, Möller T, Costa LG (2001) Activation of mitogen-activated protein kinase by muscarinic receptors in astroglial cells: role in DNA synthesis and effect of ethanol. Glia 35: 111–120.
14. Rayford W, Noble MJ, Austenfeld MA, Weigel J, Mebust WK, et al. (1997) Muscarinic cholinergic receptors promote growth of human prostate cancer cells. Prostate 30: 160–166.
15. Ogut F, Mobus V, Brock S, Dews U (2002) Muscarinic receptors in cell lines from ovarian carcinoma: negative correlation with survival of patients. Gynecol Oncol 85: 159–164.
16. Song P, Sekhon HS, Lu A, Arredondo J, Sauer D, et al. (2007) M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Res 67: 3936–3944.
17. Chen CS, Lee CH, Hsieh CD, Ho CT, Pan MH, et al. (2011) Nicotine-induced human breast cancer cell proliferation attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins. Breast Cancer Res Treat 125: 73–87.
18. Palacci L, Catassi A, Cirollo M, Cavalleri Z, Bruzzo C, et al. (2008) Role of a7-nicotinic acetylcholine receptor in human non-small cell lung cancer proliferation. Cell Prolif 41: 936–959.
19. Catassi A, Palacci L, Servent D, Sessa F, Dominioni L, et al. (2008) Targeting a7-nicotinic receptor for the treatment of pleural mesothelioma. Eur J Cancer 44: 2296–2311.
20. Shan Wong HP, Yu L, Yue Lam EK, Ki Tai EK, Kei Wu WK, et al. (2007) Nicotine promotes cell proliferation via a7-nicotinic acetylcholine receptor and catecholamine-synthesizing enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells. Toxicol Appl Pharmacol 221: 261–267.
21. Chan RJ, Ho YS, Guo HR, Wang YJ (2008) Rapid activation of ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol Sciences 104: 283–293.
22. Calleja-Macias IE, Kalantari M, Bernard HU (2009) Cholinergic signaling through nicotinic acetylcholine receptors stimulates the proliferation of cervical cancer cells: An explanation for the molecular role of tobacco smoking in cervical carcinogenesis? Int J Cancer 124: 1090–1096.
23. Wang YA, Zhou WX, Li JX, Liu YQ, Yue YJ, et al. (2005) Anticonvulsant effects of phencynonate hydrochloride and other anticholinergic drugs in soman poisoning: neurochemical mechanisms. Life Sci 78: 210–223.

24. Shen W, Gan J, Xu S, Jiang G, Wu H (2009) Penicillamine hydrochloride attenuates LPS-induced acute lung injury involvement of NF-kappaB pathway. Pharmacol Res 60: 296–302.

25. Lin CH, Chang GJ, Su MJ, Wu YC, Teng CM, et al. (1994) Pharmacological characteristics of linodrine, isolated from Fissistigma glaucescens, a novel muscarinic receptor antagonist in guine-pigs. Br J Pharmacol 113: 273–281.

26. Martinez-Moreno P, Nieto-Cerín S, Torres-Lanzas J, Ruiz-Espejo F, Tovar-Zapata L, et al. (2000) Cholinesterase activity of human lung tumours varies according to their histological classification. Carcinogenesis 21: 429–436.

27. Niu WZ, Zhao DL, Liu CG (1990) The effects of a new cholinolytic–8018–and its optical isomers on the central muscarinic and nicotinic receptors. Arch Int Pharmacodyn Ther 304: 64–74.

28. Harbou JW, Douglas CD (2000) Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2: E65–E67.

29. Sherr CJ (1996) Cancer cell cycles. Science (Wash DC) 274: 1672–1677.

30. Knudsen ES, Wang JY (1996) Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 271: 8313–8320.

31. Bettiher CG, White GR, Vonlanthen S, Liu X, Kappeler A, et al. (1997) G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int J Cancer 74: 536–562.

32. Hunter T, Pines J (1994) Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79: 573–582.

33. Ortega S, Malumbres M, Barbacid M (2002) Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602: 73–87.

34. Kim ES, Lee JJ, Wistuba ll (2011) Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy. Cancer Prev Res (Phila) 4: 779–82.

35. Willey JC, Broussoud A, Sleem A, Bennett WP, Cerami P, et al. (1991) Immortalization of human bronchial epithelial cells by papillomaviruses 16 or 18. Cancer Res 51: 5370–5377.

36. Hei TK, Wu LJ, Piao CQ (1997) Malignant transformation of immortalized human bronchial epithelial cells by asbestos fibers. Environ Health Perspect 105 (Suppl 5): 1085–1088.

37. Rubinstein LV, Shoemaker RH, Paul KD, Simon RM, Tosini S, et al. (1990) Comparison of in vitro anticancer drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113–1118.